JP2006506406A - 経粘膜的医薬投与形態物 - Google Patents
経粘膜的医薬投与形態物 Download PDFInfo
- Publication number
- JP2006506406A JP2006506406A JP2004548754A JP2004548754A JP2006506406A JP 2006506406 A JP2006506406 A JP 2006506406A JP 2004548754 A JP2004548754 A JP 2004548754A JP 2004548754 A JP2004548754 A JP 2004548754A JP 2006506406 A JP2006506406 A JP 2006506406A
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- active compound
- form according
- compound
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 29
- 210000000214 mouth Anatomy 0.000 claims abstract description 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 7
- -1 alkyl vinyl ether Chemical compound 0.000 claims abstract description 5
- 239000006104 solid solution Substances 0.000 claims abstract description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920001577 copolymer Polymers 0.000 claims abstract description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 3
- 239000011976 maleic acid Substances 0.000 claims abstract description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 39
- 239000000654 additive Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- SNZSSCZJMVIOCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1N2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 claims description 2
- 241000238557 Decapoda Species 0.000 claims description 2
- 206010013654 Drug abuse Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 claims description 2
- 229950000017 befloxatone Drugs 0.000 claims description 2
- 125000005313 fatty acid group Chemical group 0.000 claims description 2
- 150000002475 indoles Chemical class 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- XOLAHDCBBMDPCR-UHFFFAOYSA-N 7-azabicyclo[2.2.1]hept-3-ene Chemical compound C1C(N2)CCC2=C1 XOLAHDCBBMDPCR-UHFFFAOYSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 claims 1
- 229960002525 mecamylamine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 201000009032 substance abuse Diseases 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 235000012431 wafers Nutrition 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 210000002200 mouth mucosa Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
1.それらは迅速に溶解し、このことは活性化合物の口腔領域における吸収を可能にする目的での活性化合物と粘膜の長時間にわたる接触はないことを意味し、口腔領域での吸収は起こらないか、きわめて限られた程度にしか起こらない、
2.比較的長時間、粘膜との接触が維持されたとしても、マトリックスは足場として働くのみで、浸透を促進するものではない。
1.比較的長時間、口腔内粘膜、とくに舌小帯領域、舌の腹部領域または口の下底、すなわち口腔の非ケラチン化領域に接着し、
2.比較的長時間にわたり、迅速かつ持続的に口腔領域における吸収を可能にする形態に活性化合物を利用可能に保持し、そして
3.無味であるか、または無味の感覚を伝達する
システムを提供することである。
a)脂肪酸残基が少なくともその90%が飽和されているホスファチジルコリン中のまたは
b)a)で述べたホスファチジルコリンとマレイン酸およびアルキルビニルエーテルから構成されるコポリマーの混合物中の、
活性化合物の固溶体から構成される経粘膜投与形態の母体物質によって達成される。
Claims (11)
- 口腔内における低い溶解度により識別され、比較的長時間にわたり迅速かつ持続的に活性化合物を放出する、平板型の経粘膜的医薬投与形態物であって、
a)脂肪酸残基が少なくともその90%が飽和されているホスファチジルコリン分画中の、または
b)a)で特定されたホスファチジルコリン分画とマレイン酸およびアルキルビニルエーテルからなるコポリマーの混合物中の、
活性化合物の固溶体から、そして適当なら、さらに、医薬的に耐容性のあるアジュバントおよび添加物から構成されることを特徴とする、上記投与形態物。 - a)は少なくとも80重量%のホスファチジルコリン分画を含むことを特徴とする請求項1記載の投与形態物。
- 添加物としてポリビニルピロリドンを含むことを特徴とする請求項1または2に記載の投与形態物。
- 活性化合物は、耽溺性誘発薬物の濫用およびこれらの薬物依存の処置に適当であることを特徴とする請求項1〜3のいずれかに記載の投与形態物。
- 活性化合物は、縮合インドール誘導体および/またはその酸付加塩であることを特徴とする請求項1〜4のいずれかに記載の投与形態物。
- 活性化合物は、7−アザビシクロ (2.2.1) ヘプタン、7−アザビシクロ(2.2.1) ヘプテンおよび/またはこの化合物の誘導体であることを特徴とする請求項1〜4のいずれかに記載の投与形態物。
- 活性化合物は、エビバチジンおよび/またはこの化合物の誘導体であることを特徴とする請求項1〜4のいずれかに記載の投与形態物。
- 活性化合物はベンジリデン−アナバシエンおよびシナミリデン−アナバシエン、またはこの化合物の誘導体であることを特徴とする請求項1〜4のいずれかに記載の投与形態物。
- 活性化合物は、メカミルアミン、ハイパーリシン、CP−52655およびブプロプリオン/およびまたはそれらの誘導体の化合物群より選択されることを特徴とする請求項1〜4のいずれかに記載の投与形態物。
- 活性化合物は、オキサゾリジノン誘導体およびベフロキサトンの群より選択されることを特徴とする請求項1〜4のいずれかに記載の投与形態物。
- 活性化合物は、カンナビノイド受容体(CB1)アンタゴニストSR 141716であることを特徴とする請求項1〜4のいずれかに記載の投与形態物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10251963A DE10251963A1 (de) | 2002-11-08 | 2002-11-08 | Transmucosale pharmazeutische Darreichungsform |
PCT/EP2003/011529 WO2004041239A1 (de) | 2002-11-08 | 2003-10-17 | Transmucosale pharmazeutische darreichungsform |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006506406A true JP2006506406A (ja) | 2006-02-23 |
JP2006506406A5 JP2006506406A5 (ja) | 2006-10-05 |
Family
ID=32115381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004548754A Pending JP2006506406A (ja) | 2002-11-08 | 2003-10-17 | 経粘膜的医薬投与形態物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060013864A1 (ja) |
EP (1) | EP1558209A1 (ja) |
JP (1) | JP2006506406A (ja) |
KR (1) | KR20050084938A (ja) |
CN (1) | CN1694685A (ja) |
AU (1) | AU2003274030B2 (ja) |
BR (1) | BR0315911A (ja) |
CA (1) | CA2497848A1 (ja) |
DE (1) | DE10251963A1 (ja) |
MX (1) | MXPA05004892A (ja) |
PL (1) | PL375142A1 (ja) |
RU (1) | RU2342925C2 (ja) |
WO (1) | WO2004041239A1 (ja) |
ZA (1) | ZA200502443B (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001019378A2 (en) * | 1999-09-13 | 2001-03-22 | F. Hoffmann-La Roche Ag | Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
WO2001030288A1 (en) * | 1999-10-27 | 2001-05-03 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3706831A (en) * | 1971-05-14 | 1972-12-19 | Abbott Lab | Method for treatment of drug addiction |
SE8206744D0 (sv) * | 1982-11-26 | 1982-11-26 | Fluidcarbon International Ab | Preparat for kontrollerad avgivning av substanser |
JPS6115829A (ja) * | 1984-06-29 | 1986-01-23 | Toyobo Co Ltd | 口腔粘膜適用徐放性ニフエジピン製剤 |
DE3910543A1 (de) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
US5817679A (en) * | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
US5453523A (en) * | 1993-06-16 | 1995-09-26 | Emulsion Technology, Inc. | Process for obtaining highly purified phosphatidylcholine |
US6077846A (en) * | 1993-09-10 | 2000-06-20 | Ucb, S.A. | Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists |
US6117889A (en) * | 1994-04-01 | 2000-09-12 | University Of Virginia | 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents |
JPH07291854A (ja) * | 1994-04-26 | 1995-11-07 | Tanabe Seiyaku Co Ltd | 溶解性の改善された医薬品製剤 |
AU2703795A (en) * | 1994-06-23 | 1996-01-19 | Procter & Gamble Company, The | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
JP2001518520A (ja) * | 1997-10-03 | 2001-10-16 | キャリー メディカル コーポレイション | ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物 |
US20040028735A1 (en) * | 1997-11-14 | 2004-02-12 | Unchalee Kositprapa | Pharmaceutical formulation |
SE9803986D0 (sv) * | 1998-11-23 | 1998-11-23 | Pharmacia & Upjohn Ab | New compositions |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE10024413A1 (de) * | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
DE10032456A1 (de) * | 2000-07-04 | 2002-01-31 | Lohmann Therapie Syst Lts | Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen |
DE10107659B4 (de) * | 2001-02-19 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin |
-
2002
- 2002-11-08 DE DE10251963A patent/DE10251963A1/de not_active Withdrawn
-
2003
- 2003-10-17 JP JP2004548754A patent/JP2006506406A/ja active Pending
- 2003-10-17 KR KR1020057007931A patent/KR20050084938A/ko not_active Application Discontinuation
- 2003-10-17 US US10/533,926 patent/US20060013864A1/en not_active Abandoned
- 2003-10-17 RU RU2005113169/15A patent/RU2342925C2/ru not_active IP Right Cessation
- 2003-10-17 EP EP03758008A patent/EP1558209A1/de not_active Ceased
- 2003-10-17 CA CA002497848A patent/CA2497848A1/en not_active Abandoned
- 2003-10-17 MX MXPA05004892A patent/MXPA05004892A/es active IP Right Grant
- 2003-10-17 CN CNA2003801007385A patent/CN1694685A/zh active Pending
- 2003-10-17 PL PL03375142A patent/PL375142A1/xx not_active Application Discontinuation
- 2003-10-17 WO PCT/EP2003/011529 patent/WO2004041239A1/de active Application Filing
- 2003-10-17 AU AU2003274030A patent/AU2003274030B2/en not_active Ceased
- 2003-10-17 BR BR0315911-6A patent/BR0315911A/pt not_active IP Right Cessation
-
2005
- 2005-03-24 ZA ZA200502443A patent/ZA200502443B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001019378A2 (en) * | 1999-09-13 | 2001-03-22 | F. Hoffmann-La Roche Ag | Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
WO2001030288A1 (en) * | 1999-10-27 | 2001-05-03 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
Also Published As
Publication number | Publication date |
---|---|
KR20050084938A (ko) | 2005-08-29 |
MXPA05004892A (es) | 2005-07-22 |
BR0315911A (pt) | 2005-09-13 |
AU2003274030A1 (en) | 2004-06-07 |
ZA200502443B (en) | 2005-09-26 |
US20060013864A1 (en) | 2006-01-19 |
RU2005113169A (ru) | 2006-01-20 |
RU2342925C2 (ru) | 2009-01-10 |
EP1558209A1 (de) | 2005-08-03 |
CA2497848A1 (en) | 2004-05-21 |
AU2003274030B2 (en) | 2008-09-04 |
WO2004041239A1 (de) | 2004-05-21 |
CN1694685A (zh) | 2005-11-09 |
DE10251963A1 (de) | 2004-05-19 |
PL375142A1 (en) | 2005-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3381220B2 (ja) | 急性疾患の処置のための製薬学的組成物 | |
JP5717946B2 (ja) | ポリビニルアルコール−ポリエチレングリコールグラフト共重合体を含有する泡状ウェハ | |
JP6448096B2 (ja) | 舌下及び頬用フィルム組成物 | |
CA2414665C (en) | Rapidly disintegrating dosage form for releasing active ingredients in the oral cavity or in body cavities | |
JP5752122B2 (ja) | 舌下及び口腔用膜組成物 | |
KR101367814B1 (ko) | 위장체류 제제 및 이의 제조 방법 | |
JP2017206517A (ja) | 薬物置換療法のためのブプレノルフィンウェハー | |
MX2008010548A (es) | Peliculas orales disgregables. | |
MX2012001573A (es) | Composiciones de película sublinguales y bucales. | |
KR102398857B1 (ko) | 높은 단위 면적 당 질량을 갖는 신속 붕해성의 포말 웨이퍼 | |
JPH11501652A (ja) | 有機組成物の改良 | |
CA2392810A1 (en) | A rapid acting freeze dired oral pharmaceutical composition for treating migraine | |
JP2006506406A (ja) | 経粘膜的医薬投与形態物 | |
JP4629730B2 (ja) | 薬物ののみ易さを改善するための医薬組成物及びその調製方法 | |
NZ538707A (en) | Transmucosal pharmaceutical administration form for treating the abuse of and dependence on addictive drugs | |
Dave et al. | A review on promising novel drug delivery system-bioadhesive drug delivery system | |
JPS63250319A (ja) | 口腔内に適用する製剤 | |
CA2506712C (en) | Rapidly-decomposing administrable form for releasing ingredients in the oral cavity or in bodily cavities | |
JPWO2003075918A1 (ja) | 塩酸ピルジカイニド含有錠剤(湿式) | |
Chen | Polymeric films for buccal drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060814 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100413 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100420 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101102 |